Charles Schwab
TRDA icon

Charles Schwab’s Entrada Therapeutics TRDA Stock Holding History

Charles Schwab’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.45M Sell
197,136
-17,615
-8% -$169K ﹤0.01% 2893
2026
Q1 		$2.71M Sell
214,751
-6,518
-3% -$74.7K ﹤0.01% 2628
2025
Q4 		$2.27M Buy
221,269
+36,010
+19% +$304K ﹤0.01% 2725
2025
Q3 		$1.07M Sell
185,259
-18,434
-9% -$108K ﹤0.01% 2927
2025
Q2 		$1.37M Buy
203,693
+10,976
+6% +$88.3K ﹤0.01% 2792
2025
Q1 		$1.74M Sell
192,717
-4,410
-2% -$55K ﹤0.01% 2656
2024
Q4 		$3.41M Buy
197,127
+11,143
+6% +$202K ﹤0.01% 2514
2024
Q3 		$2.97M Buy
185,984
+23,643
+15% +$373K ﹤0.01% 2588
2024
Q2 		$2.31M Buy
162,341
+5,712
+4% +$81.2K ﹤0.01% 2660
2024
Q1 		$2.22M Buy
156,629
+5,271
+3% +$74.5K ﹤0.01% 2557
2023
Q4 		$2.28M Sell
151,358
-3,866
-2% -$57.3K ﹤0.01% 2572
2023
Q3 		$2.45M Buy
155,224
+12,807
+9% +$202K ﹤0.01% 2542
2023
Q2 		$2.16M Buy
142,417
+52,939
+59% +$729K ﹤0.01% 2523
2023
Q1 		$1.3M Buy
89,478
+508
+0.6% +$6.78K ﹤0.01% 2650
2022
Q4 		$1.2M Buy
88,970
+1,111
+1% +$19.5K ﹤0.01% 2720
2022
Q3 		$1.39M Buy
87,859
+45,077
+105% +$572K ﹤0.01% 2700
2022
Q2 		$522K Sell
42,782
-25,922
-38% -$197K ﹤0.01% 3060
2022
Q1 		$646K Buy
68,704
+4,685
+7% +$50.2K ﹤0.01% 3021
2021
Q4 		$1.1M Buy
+64,019
New +$1.55M ﹤0.01% 2873

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Charles Schwab's TRDA Position: Q2 2026 in Review

Charles Schwab reduced its Entrada Therapeutics (TRDA) stake by 8.2% in Q2 2026, selling an estimated $169K and leaving 197,136 shares worth $1.45M. The position accounts for ﹤0.01% of the portfolio, ranked #2893.

Charles Schwab first reported a position in TRDA in Q4 2021 and has held it in 19 quarters since. The position peaked at $3.41M in Q4 2024. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Charles Schwab held 197,136 shares of Entrada Therapeutics worth $1.45M as of Q2 2026.
  • Charles Schwab sold 17,615 Entrada Therapeutics shares in Q2 2026, an estimated $169K.
  • Entrada Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2893 holding.
  • Charles Schwab first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Charles Schwab's Entrada Therapeutics position peaked at $3.41M in Q4 2024.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.